ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 03/29/22

Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022. An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash. ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has filed an application with New Zealand authorities seeking permission to begin a phase 1/2 trial of ARO-MUC5AC, its candidate for  asthma and other muco-obstructive pulmonary diseases. ARO-MUC5AC is an RNAi therapeutic that is designed to r...

- Company to Host Pulmonary R&D Day on May 26, 2022 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MUC5AC, the company’s investigational RNA interference (RNAi...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for ad...

My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and former market darlings. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helpi...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached full planned enrollment of more than 180 people in the phase 2b trial of ARO-ANG3 to treat patients with mixed dyslipidemia. The study, dubbed ARCHES-2, is expected to be completed around the end 2022 and the company intends to report topline da...

- Topline data expected in the first half of 2023 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the company’s investigational RNA...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) dosed the first person in a phase 1/2 study of ARO-C3, an RNA interference (RNAi) therapeutic aimed at reducing the production of complement component 3 (C3) and be potential therapy for various complement mediated diseases. The study, dubbed AROC3-1001...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) a...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear ce...